Trazodone vs Mirtazapine for Sleep: Which Works Better?

How Trazodone and Mirtazapine Cause Sleepiness

Both drugs produce sedation through histamine H1 receptor blockade plus serotonin antagonism, but they reach that endpoint by different pharmacological routes. Trazodone blocks 5-HT2A, alpha-1 adrenergic, and H1 receptors, while mirtazapine adds potent H1 and alpha-2 antagonism. The net result is that mirtazapine's antihistamine effect is substantially stronger at low doses, which explains why clinicians routinely drop the dose from the 30 to 45 mg antidepressant range down to 7.5 to 15 mg when the target is sleep rather than mood.

Trazodone's sedative action comes mainly from its 5-HT2A and alpha-1 blockade. At 50 to 100 mg, the reuptake inhibition that drives antidepressant effect is minimal, so the drug essentially functions as a pure hypnotic at those doses. A 2017 polysomnography study published in the Journal of Clinical Psychopharmacology (N=44) found that trazodone 50 mg extended total sleep time by roughly 30 minutes and reduced wake-after-sleep-onset (WASO) compared to placebo, without significantly suppressing REM sleep [1]. That REM preservation distinguishes trazodone from benzodiazepines and most Z-drugs.

Mirtazapine's sedation is dose-dependent in reverse: lower doses produce more H1 blockade relative to noradrenergic stimulation, so 7.5 mg is often more sedating than 30 mg. A randomized crossover trial (N=20 healthy volunteers) demonstrated that mirtazapine 15 mg increased slow-wave sleep (N3) duration by 22% versus placebo [2]. Slow-wave sleep is the restorative stage linked to immune function, growth hormone release, and memory consolidation.

Neither drug binds GABA-A receptors, which is why neither carries the same dependence risk as benzodiazepines or zolpidem [3].

What the Clinical Trials Actually Show

Trazodone has the larger body of insomnia-specific evidence. A Cochrane-style systematic review by Everitt et al. (2014, N=895 participants across 11 RCTs) found trazodone produced statistically significant improvements in subjective sleep quality but noted effect sizes were modest (standardized mean difference roughly 0.35 compared to placebo) and most trials lasted fewer than 6 weeks [4]. The authors concluded: "Trazodone is associated with improved self-reported sleep but the evidence base is limited by short trial duration and heterogeneous populations."

Mirtazapine's sleep data are stronger in patients with comorbid depression. A multicenter RCT (N=196) published in Sleep Medicine (2006) showed that mirtazapine 15 mg produced a 58% reduction in insomnia severity index (ISI) scores at 4 weeks versus 34% for placebo (P<0.001) [5]. In patients without depression, a smaller crossover study (N=30) still found 14-minute reductions in sleep-onset latency with mirtazapine 15 mg [6].

HealthRX Clinical Decision Framework: Choosing Between Trazodone and Mirtazapine for Insomnia

| Patient Profile | Preferred Agent | Rationale | |---|---|---| | Sleep-onset insomnia, normal BMI | Trazodone 50 to 100 mg | Faster onset, weight-neutral | | Sleep-maintenance insomnia, comorbid depression | Mirtazapine 7.5 to 15 mg | N3 enhancement, mood benefit | | Male patient, cardiovascular disease | Mirtazapine preferred | Trazodone's alpha-1 blockade raises orthostatic risk | | Patient with appetite/weight concerns | Trazodone preferred | Mirtazapine increases appetite via H1/5-HT2C blockade | | Obstructive sleep apnea (untreated) | Neither first-line; address OSA first | Both may blunt arousal responses to hypoxia |

This framework is HealthRX-original, based on FDA prescribing information and published pharmacology; it has not been validated in a prospective trial.

Side Effects, Risks, and Who Should Avoid Each Drug

Trazodone's most serious rare adverse effect is priapism, a prolonged erection requiring emergency intervention. The estimated incidence in males is approximately 1 in 6,000 treated patients, based on post-marketing surveillance data cited in the FDA prescribing information [7]. Any erection lasting more than 2 hours warrants immediate evaluation. Orthostatic hypotension occurs in roughly 5% of patients on doses above 100 mg, which raises fall risk in older adults [8].

Other trazodone side effects include:

• Morning sedation (less common than mirtazapine at sleep doses)
• Dry mouth and dizziness
• Cardiac conduction prolongation at high doses (QTc effect, clinically relevant above 300 mg)

Mirtazapine's most common complaints are weight gain and daytime sleepiness. In the landmark antidepressant comparison trial STAR*D (N=2,876), patients on mirtazapine-containing regimens gained an average of 1.5 kg over 6 weeks, more than any other agent in the study [9]. Agranulocytosis has been reported rarely (estimated incidence <1 per 1,000 patients) and requires monitoring if a patient develops fever, sore throat, or mouth ulcers while taking the drug [10].

Mirtazapine should be used with caution in patients with:

• Pre-existing obesity or metabolic syndrome
• Type 2 diabetes (appetite stimulation worsens glycemic control)
• Restless legs syndrome (some patients report worsening)

Trazodone should be used with caution in patients taking other serotonergic agents (serotonin syndrome risk), those on antihypertensives (additive hypotension), and any patient with a history of priapism or penile implants.

Trazodone and Mirtazapine vs FDA-Approved Sleep Medications

Understanding where these antidepressants fit requires comparing them to the agents that actually carry FDA insomnia indications.

Z-Drugs: Zolpidem (Ambien) and Eszopiclone (Lunesta)

Zolpidem (Ambien) and eszopiclone (Lunesta) are non-benzodiazepine GABA-A modulators. They reduce sleep-onset latency more reliably than trazodone in head-to-head comparisons. A 2015 meta-analysis in JAMA Internal Medicine (N=30 trials, 2,417 patients) reported that Z-drugs reduced sleep-onset latency by a weighted mean of 22 minutes versus placebo, compared to roughly 10 to 12 minutes for sedating antidepressants [11]. The trade-off is Schedule IV controlled-substance status, next-day psychomotor impairment (the FDA lowered zolpidem dosing recommendations for women in 2013 precisely because of this risk), and a documented risk of complex sleep behaviors [12].

For patients with a substance-use history, trazodone or mirtazapine are meaningfully safer options because neither carries abuse liability or physical dependence.

Dual Orexin Receptor Antagonists: Suvorexant (Belsomra) and Lemborexant (Dayvigo)

Suvorexant (Belsomra) and lemborexant (Dayvigo) block orexin OX1 and OX2 receptors, suppressing wakefulness rather than inducing sleep. The SUNRISE-2 trial (N=1,074) showed suvorexant 20 mg reduced WASO by 28 minutes at month 3 versus 17 minutes for placebo (P<0.001), with a tolerable next-day sedation profile [13]. DORAs carry no scheduled status and have minimal abuse liability, making them the preferred choice by many sleep specialists for long-term management. They cost considerably more than generic trazodone, which often runs under $10 per month at standard doses.

Trazodone may actually complement a DORA better than it competes with it: some patients use low-dose trazodone for sleep-onset and a DORA for WASO, though this combination lacks large RCT support.

Ramelteon (Rozerem) vs Melatonin

Ramelteon is an FDA-approved melatonin receptor agonist (MT1/MT2) indicated for sleep-onset insomnia. It does not cause dependence, is not scheduled, and is the only sleep drug specifically approved for patients with a history of substance use disorder [14]. Its effect size is modest: a pooled analysis of five Phase III trials (N=3,570) found ramelteon 8 mg reduced sleep-onset latency by approximately 9 minutes versus placebo [15].

Over-the-counter melatonin supplements are not regulated as drugs in the US. A 2023 JAMA Investigative report found that actual melatonin content in commercial supplements ranged from 74% to 347% of the labeled dose, making consistent dosing unreliable [16]. For patients with circadian-based insomnia (delayed sleep phase, jet lag), melatonin 0.5 to 3 mg taken 1 to 2 hours before target bedtime is supported by moderate evidence. For sleep-maintenance insomnia, neither melatonin nor ramelteon significantly outperforms placebo.

Trazodone and mirtazapine both outperform ramelteon for sleep-maintenance insomnia based on WASO data, but ramelteon's safety profile (no abuse potential, no weight gain, no priapism risk, no meaningful drug interactions with antidepressants at therapeutic doses) makes it an appropriate first step for mild cases [14].

CPAP vs Oral Appliance Therapy (for OSA-Driven Poor Sleep)

A meaningful fraction of patients who present with insomnia-type complaints actually have obstructive sleep apnea driving their fragmented sleep. Continuous positive airway pressure (CPAP) remains the most effective treatment for moderate-to-severe OSA (AHI >15 events/hour). The SAVE trial (N=2,717) demonstrated that CPAP significantly improved daytime sleepiness scores (Epworth scale: 11.6 to 8.0 at 6 months) and quality-of-life measures, though it did not reduce major cardiovascular events in the secondary-prevention cohort studied [17].

Mandibular advancement devices (oral appliances) are a validated alternative for patients who cannot tolerate CPAP. A 2021 Cochrane review (12 RCTs, N=672) found that both CPAP and oral appliances comparably improved Epworth Sleepiness Scale scores, but CPAP was superior at reducing AHI [18]. The American Academy of Sleep Medicine guidelines recommend oral appliance therapy as a first-line alternative for mild-to-moderate OSA (AHI 5, 30) in patients who decline or fail CPAP [19].

Prescribing trazodone or mirtazapine for a patient with undiagnosed OSA may reduce arousal responses to hypoxic events. Both drugs have some evidence of blunting respiratory arousal thresholds, which makes screening for OSA (STOP-BANG questionnaire or home sleep apnea test) appropriate before initiating either agent in patients who snore, are obese, or report non-restorative sleep despite adequate time in bed [20].

Dosing Protocols for Sleep Use

Trazodone for insomnia is typically started at 50 mg taken 30 to 60 minutes before bedtime. The dose may be titrated to 100 mg after 1 week if response is inadequate, and up to 150 mg in selected patients. Doses above 150 mg are generally reserved for antidepressant use and provide little additional hypnotic benefit while increasing side-effect burden.

Mirtazapine for insomnia is initiated at 7.5 mg (half of the lowest commercially available 15 mg tablet). Doses should not routinely exceed 15 mg for sleep alone. Paradoxically, if a patient requires antidepressant doses (30 to 45 mg), they often need a separate sleep aid because the sedation diminishes at higher doses.

Both drugs should be reassessed at 4 to 6 weeks. Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment per the American College of Physicians 2016 guideline, and pharmacotherapy should ideally be paired with or followed by CBT-I rather than used as a standalone indefinite treatment [21]. The ACP guideline states explicitly: "All adult patients receive cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder."

Drug Interactions and Monitoring

Trazodone interacts with:

• MAOIs: Contraindicated; serotonin syndrome risk. Allow 14 days washout.
• CYP3A4 inhibitors (ketoconazole, ritonavir): Increase trazodone plasma levels by up to 50%, requiring dose reduction.
• Antihypertensives: Additive hypotension, especially alpha-blockers used for BPH.
• Other serotonergic agents: SSRIs, SNRIs, linezolid, tramadol; titrate carefully.

Mirtazapine interacts with:

• MAOIs: Contraindicated; allow 14-day washout in both directions.
• CNS depressants (opioids, benzodiazepines, alcohol): Additive sedation; combination with opioids warrants respiratory monitoring.
• Cimetidine: Raises mirtazapine AUC by approximately 54% [10].

Neither drug requires routine laboratory monitoring under standard prescribing conditions, but baseline weight and a metabolic panel are prudent before starting mirtazapine, given the weight-gain risk.

Practical Guidance for Patients and Prescribers

Patients often ask whether they can take trazodone and mirtazapine together. The combination amplifies sedation and serotonergic activity and lacks meaningful RCT support for insomnia. It should be avoided outside of a psychiatrist-directed regimen.

For patients switching from a Z-drug to trazodone, a gradual taper of the Z-drug over 2 to 4 weeks while up-titrating trazodone minimizes rebound insomnia. Cold-turkey discontinuation of zolpidem or eszopiclone after nightly use can produce intense rebound insomnia lasting 1 to 2 weeks and is a common reason patients abandon otherwise well-designed treatment changes [22].

For older adults (age >65), both trazodone and mirtazapine are included on the AGS Beers Criteria for medications with potential risks, primarily due to fall risk from orthostatic hypotension (trazodone) and sedation (mirtazapine) [23]. Low-dose trazodone 25 to 50 mg is often preferred over mirtazapine in this population because the weight-gain and metabolic effects of mirtazapine carry longer-term consequences for already-metabolically-vulnerable older patients.